Cara Therapeutics Announces KOMFORT Data Accepted for Late-Breaking Presentation at the 31st EADV Congress
Cara Therapeutics (Nasdaq: CARA) announced it will present data from the Phase 2 trial of oral difelikefalin for treating moderate-to-severe pruritus in patients with notalgia paresthetica. The presentation is scheduled for September 8, 2022, during the 31st EADV Congress in Milan, Italy. The trial, known as KOMFORT, aims to assess the efficacy of difelikefalin in this patient population. The company is also advancing its pipeline, including a Phase 3 program for pruritus in patients with advanced chronic kidney disease.
- Data presentation from Phase 2 trial of oral difelikefalin could enhance company visibility.
- Continued development of oral difelikefalin may expand treatment options for patients suffering from pruritus.
- None.
Oral presentation will include data from the Phase 2 trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica
STAMFORD, Conn., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced data from the KOMFORT Phase 2 clinical trial evaluating oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica will be presented during a late-breaking news session at the 31st European Academy of Dermatology and Venereology (EADV) Congress, to be held September 7-10, 2022, in Milan, Italy.
Details of the late-breaking oral presentation are as follows:
Title: A Phase 2 Study of Oral Difelikefalin for Moderate-to-Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)
Session: D1T01.3: Late breaking news
Session Date and Time: September 8, 2022, 14.15-17.30 CEST
Presenter: Mark Lebwohl, MD, Icahn School of Medicine at Mount Sinai, New York, NY
About Cara Therapeutics
Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. The Company has completed the placebo-controlled phase of a Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. A Phase 2 proof-of-concept trial in primary biliary cholangitis patients with moderate-to-severe pruritus is ongoing. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.
MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com
INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com
FAQ
When will Cara Therapeutics present the Phase 2 trial data for oral difelikefalin?
What is the focus of the KOMFORT Phase 2 trial conducted by Cara Therapeutics?
Where is the EADV Congress taking place?
What company is responsible for the oral difelikefalin trial?
What is the significance of the oral presentation by Cara Therapeutics at the EADV Congress?
